Amyris brought its farnesene production platform to scale, but returned to low-volume applications following financial trouble

May 24, 2018 | Case Study

Amyris is a synthetic biology company that utilizes high-throughput screening to evaluate genetically engineered strains of yeast that produce isoprenoid compounds. The company has developed software and hardware platforms that allow its scientists to design and build over 1,000 molecules per month. Over the past few years, the majority of Amyris' resources were diverted from developing new pathways and instead dedicated toward ramping up and optimizing the production of farnesene (C15H24), a platform molecule with a variety of derivatives and with both high- and low-volume applications. Amyris prioritized the high-volume derivatives in 2011 and began the construction of a 40,000 tpa capacity commercial facility named Brotas 1.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978